AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA
→ AstraZeneca swept out two early-stage cancer drugs in its Q4 call on Friday. Out to the dustbin goes the anti-ASCT2 antibody-drug conjugate MEDI7247 and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.